Skip to main content
. 2021 Mar 11;10(3):LMT47. doi: 10.2217/lmt-2020-0027

Table 2. . Best objective response to treatment by RECIST 1.1 of 100 patients after use of immunotherapy.

Objective response rate Patients, n (%)
Complete 2 (2%)
Partial 11 (11%)
Stable disease 61 (61%)
Progressive disease 4 (4%)
Unevaluable 22 (22%)